NCT02239614View on ClinicalTrials.gov

TDENV PIV and LAV Dengue Prime-boost Strategy

PHASE1CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

February 17, 2016

Study Completion Date

February 17, 2017

Conditions
Dengue
Interventions
BIOLOGICAL

TDENV-LAV

0.5 mL of the post-transfection LAV F17 vaccine

BIOLOGICAL

TDENV-PIV 4 µg + alum adjuvant

0.5 mL of DENV serotypes 1-4 (4 µg / serotype) in alum adjuvant

Trial Locations (1)

20910

Clinical Trials Center, Walter Reed Army Institute of Research (CTC, WRAIR), Silver Spring

All Listed Sponsors
lead

U.S. Army Medical Research and Development Command

FED

NCT02239614 - TDENV PIV and LAV Dengue Prime-boost Strategy | Biotech Hunter | Biotech Hunter